Despite the availability of pharmacological and psychosocial tools for the treatment of alcohol use disorders (AUD), more than 60% of patients who reach the detoxification and abstinence phases experience relapse. This high relapse rate underscores the urgent need to identify new pharmacological strategies capable of improving therapeutic outcomes, reducing the social and health burden associated with AUD, and ultimately enhancing patients’ quality of life.
The CANNABIAL project will address this need by identifying specific biomarkers—particularly changes in gene expression in lymphocytes—associated with the different phases of alcohol use disorder (AUD), including detoxification, withdrawal, and relapse, in patients recruited within the project coordinated with Dr. Rubio’s group. In addition, the use of animal models that replicate key characteristics of AUD will enable the identification of specific biomarkers, including gene‑expression changes in lymphocytes and in selected brain nuclei.
In both patients and mice, the involvement of the endogenous cannabinoid system and other markers related to reinforcement and motivation will be examined. Furthermore, in the animal model, the therapeutic potential of a monoacylglycerol lipase (MAGL) inhibitor—administered alone or in combination with drugs commonly used in clinical practice—will be evaluated for its ability to modulate consumption, ethanol‑related motivation, and relapse. All studies in both patients and animals will be conducted in males and females.
The results obtained in the CANNABIAL project will enable the identification of biomarkers of alcohol use disorder (AUD) at different stages of dependence, incorporating a gender perspective, with the aim of achieving more accurate diagnosis and designing personalized, more effective, and safer pharmacotherapeutic strategies.

